These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17518123)

  • 21. Erythropoietin: the swinging pendulum.
    Oster HS; Neumann D; Hoffman M; Mittelman M
    Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 23. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
    Khuri FR
    N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
    [No Abstract]   [Full Text] [Related]  

  • 24. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 25. Darbepoetin alfa and chronic kidney disease.
    Minnerup J; Schäbitz WR
    N Engl J Med; 2010 Feb; 362(7):653-4; author reply 655. PubMed ID: 20187258
    [No Abstract]   [Full Text] [Related]  

  • 26. Taking a subq approach to EPO: experience in the clinic.
    Wish J
    Nephrol News Issues; 2007 Oct; 21(11):68. PubMed ID: 17970511
    [No Abstract]   [Full Text] [Related]  

  • 27. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
    Vaziri ND; Zhou XJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
    [No Abstract]   [Full Text] [Related]  

  • 28. CERA: third-generation erythropoiesis-stimulating agent.
    Topf JM
    Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).
    Goldsmith D; Covic A
    Nephrol Dial Transplant; 2010 Jun; 25(6):1734-7. PubMed ID: 20200007
    [No Abstract]   [Full Text] [Related]  

  • 30. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 31. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anemia of chronic kidney disease and end-stage renal disease: are there unique issues in disadvantaged populations?
    Obrador GT
    Ethn Dis; 2009; 19(1 Suppl 1):S1-52-5. PubMed ID: 19484876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New limits advised for anemia drugs.
    Mitka M
    JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
    [No Abstract]   [Full Text] [Related]  

  • 34. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 35. Erythropoiesis-stimulating agents--time for a reevaluation.
    Unger EF; Thompson AM; Blank MJ; Temple R
    N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
    [No Abstract]   [Full Text] [Related]  

  • 36. Cancer- and treatment-related anemia.
    Rodgers GM; Cella D; Chanan-Khan A; Chesney C; Cleeland C; Coccia PF; Demetri GD; Djulbegovic B; Garst JL; Gore M; Kraut EH; Lin WC; Millenson M; Mock V; Reinke D; Rosenthal J; Sabbatini P
    J Natl Compr Canc Netw; 2005 Nov; 3(6):772-89. PubMed ID: 16316613
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.
    Ofsthun NJ; Lazarus JM
    Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA panel scrutinizes safety of anti-anemia drugs.
    Randal J
    J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966
    [No Abstract]   [Full Text] [Related]  

  • 39. Amgen's point of view on epoetins.
    Seidenberg B; Perlmutter RM
    Lancet Oncol; 2004 Apr; 5(4):206-7. PubMed ID: 15050950
    [No Abstract]   [Full Text] [Related]  

  • 40. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.